Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Lowered by Rhumbline Advisers

Rhumbline Advisers reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,644 shares of the biopharmaceutical company’s stock after selling 514 shares during the period. Rhumbline Advisers owned 0.12% of Intra-Cellular Therapies worth $10,494,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in ITCI. True Wealth Design LLC acquired a new stake in Intra-Cellular Therapies in the third quarter worth approximately $32,000. GAMMA Investing LLC lifted its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the period. Capital Performance Advisors LLP bought a new position in Intra-Cellular Therapies during the third quarter valued at about $74,000. Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies during the third quarter worth about $97,000. Finally, Quarry LP raised its position in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Insider Activity

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Price Performance

NASDAQ:ITCI opened at $128.60 on Monday. The stock has a market cap of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a fifty-two week low of $62.78 and a fifty-two week high of $128.77. The stock’s 50-day moving average is $110.27 and its two-hundred day moving average is $89.84.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ITCI has been the subject of several research reports. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.